Bosentan - GL PharmTech
Latest Information Update: 10 Oct 2021
Price :
$50 *
At a glance
- Originator GL PharmTech
- Class Anti-inflammatories; Anti-ischaemics; Antiasthmatics; Antihypertensives; Benzene derivatives; Foot disorder therapies; Heart failure therapies; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides; Urologics
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in South Korea (PO, Tablet)
- 01 Nov 2011 Phase-I clinical trials in Pulmonary arterial hypertension in South Korea (PO)